These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15301041)

  • 41. Pharmacological treatment for pubertal progression in boys with delayed or slow progression of puberty: A small-scale randomized study with testosterone enanthate and testosterone undecanoate treatment.
    Österbrand M; Fors H; Norjavaara E
    Front Endocrinol (Lausanne); 2023; 14():1158219. PubMed ID: 37124726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.
    Meuleman EJ; Legros JJ; Bouloux PM; Johnson-Levonas AO; Kaspers MJ; Elbers JM; Geurts TB; Meehan AG;
    Aging Male; 2015; 18(3):157-63. PubMed ID: 26030346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome.
    Park MG; Yeo JK; Cho DY; Kim JW; Kim JW; Oh MM; Kim JJ; Moon du G
    J Sex Med; 2015 Apr; 12(4):966-74. PubMed ID: 25648342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes in markers of bone metabolism during dexamethasone treatment for chronic lung disease in preterm infants.
    Ng PC; Lam CW; Wong GW; Lee CH; Cheng PS; Fok TF; Chan IH; Wong E; Cheung K; Lee SY
    Arch Dis Child Fetal Neonatal Ed; 2002 Jan; 86(1):F49-54. PubMed ID: 11815549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals.
    Meriggiola MC; Armillotta F; Costantino A; Altieri P; Saad F; Kalhorn T; Perrone AM; Ghi T; Pelusi C; Pelusi G
    J Sex Med; 2008 Oct; 5(10):2442-53. PubMed ID: 18624972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term changes in bone formation markers following growth hormone (GH) treatment in short prepubertal children with a broad range of GH secretion.
    Andersson B; Swolin-Eide D; Magnusson P; Albertsson-Wikland K
    Clin Endocrinol (Oxf); 2015 Jan; 82(1):91-9. PubMed ID: 24818653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term changes in urinary growth hormone excretion and lower leg length in healthy children.
    Ahmed SF; Barnes SI; Wallace WH; Kelnar CJ
    Horm Res; 1997; 48(2):72-5. PubMed ID: 9251923
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men.
    Fennell C; Sartorius G; Ly LP; Turner L; Liu PY; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):102-9. PubMed ID: 19891698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover.
    Guo CY; Jones TH; Eastell R
    J Clin Endocrinol Metab; 1997 Feb; 82(2):658-65. PubMed ID: 9024272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men.
    Meriggiola MC; Costantino A; Cerpolini S; Bremner WJ; Huebler D; Morselli-Labate AM; Kirsch B; Bertaccini A; Pelusi C; Pelusi G
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5818-26. PubMed ID: 14671175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Which androgen replacement therapy for women?
    Buckler HM; Robertson WR; Wu FC
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3920-4. PubMed ID: 9814469
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E; Büchter D; Von Eckardstein S; Abshagen K; Simoni M; Behre HM
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate.
    Meriggiola MC; Costantino A; Saad F; D'Emidio L; Morselli Labate AM; Bertaccini A; Bremner WJ; Rudolph I; Ernst M; Kirsch B; Martorana G; Pelusi G
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2005-14. PubMed ID: 15634716
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of bone alkaline phosphatase and iPTH with some basic biochemical markers in predialysis and dialysis patients.
    Milinković NL; Majkic-Singh NT; Ignjatović SD; Lezaić VD; Pejanović SD; Jovanovic DB
    Clin Lab; 2012; 58(7-8):747-53. PubMed ID: 22997975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M; Nieschlag E
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Biochemical markers of bone formation activity in children with neoplasms].
    Muszyńska-Rosłan K; Krawczuk-Rybak M; Protas P; Siedlecka E; Wiśniewska M; Wołczyński S
    Wiad Lek; 2005; 58(1-2):29-35. PubMed ID: 15991550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthate.
    Partsch CJ; Weinbauer GF; Fang R; Nieschlag E
    Eur J Endocrinol; 1995 Apr; 132(4):514-9. PubMed ID: 7711892
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.